Numerous small pharmaceutical manufacturers in Bangladesh are marketing substandard drugs, often deliberately using inadequate levels of active ingredients. Stricter application of the national drug policy is necessary, notably in regard to the issuing of licences and the sanctions applied to firms breaking the law.